The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
β-Cell Function and the Development of Diabetes-Related Complications in the Diabetes Control and Complications Trial
Open accessAbstract
In patients with type 1 diabetes, measurement of connecting peptide (C-peptide), cosecreted with insulin from the islets of Langerhans, permits estimation of remaining β-cell secretion of insulin. In this retrospective analysis to distinguish the incremental benefits of residual β-cell activity in type 1 diabetes, stimulated (90 min following ingestion of a mixed meal) C-peptide levels at entry in the Diabetes Control and Complications Trial (DCCT) were related to measures of diabetic retinopathy and nephropathy and to incidents of severe hypoglycemia. Based on the analytical sensitivity of the assay (0.03 nmol/l) and study entry criteria, the DCCT subjects were divided into four groups of stimulated C-peptide responses: ≤0.03, 0.04–0.20, 0.21–0.50 nmol/l at entry, and 0.21–0.50 nmol/l at entry and at least 1 year later (sustained C-peptide secretion). Uniformly in the intensive and partially in the conventional DCCT treatment groups, any C-peptide secretion, but especially at higher and sustained levels of stimulated C-peptide, was associated with reduced incidences of retinopathy (both a single three-step change and a repeated three-step change on the Early Treatment of Diabetic Retinopathy Study [ETDRS] scale at the next 6 month visit) and nephropathy (both albuminuria >40 mg/24 h once and repeated at the next annual visit). There were also differences in severe hypoglycemia across C-peptide levels in both treatment groups. In the intensively treated cohort there were essentially identical prevalences of severe hypoglycemia (∼65% of participants) in the first three groups; however, those subjects with mixed-meal stimulated C-peptide level >0.20 nmol/l for at least baseline and the first annual visit in the DCCT experienced a reduced prevalence of ∼30%. Therefore, even modest levels of β-cell activity at entry in the DCCT were associated with reduced incidences of retinopathy and nephropathy. Also, continuing C-peptide (insulin) secretion is important in avoiding hypoglycemia (the major complication of intensive diabetic therapy).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although this endogenous secretion is typically low, maintenance is important since it is associated with less retinopathy and less severe hypoglycaemia at later stages of the disease.86”
From Type 1 diabetes (2014) · cites this paper as [86]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“natural history studies, intervention trials, and transplantation studies consistently show that higher Cpeptide responses to a mixed meal are associated with improved glycaemic control, fewer hypoglycaemic episodes, and reduced longterm complications.[55][56][57]”
From The future of type 1 diabetes therapy (2025) · cites this paper as [57]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“This finding is noteworthy because in the Diabetes Control and Complications Trial68,69 persistent C-peptide secretion was associated with reduced development of retinopathy, nephropathy, and hypoglycaemia.”
From Type 1 diabetes (2018) · cites this paper as [69]
In the citing paper
“In addition, we analysed two other thresholds: UCPCR≥0.03 nmol/mmol and ≥0.2nmol/mmol, which are equivalent to serum C peptide of 30 pmol/L (a common historical limit of detection(3; 11; 12)) and 200 pmol/L (a clinically defined level associated with reduced microvascular complications and hypoglycaemia(13)).”
From Most people with long-duration type 1 diabetes in a large population-based study are insulin microsecretors (2015) · cites this paper as [11]
In the citing paper
“The strongest evidence to date, however, finds that while higher and sustained levels of C-peptide are most beneficial, even modest levels of β-cell function in some with long-term disease are associated with lower rates of hypoglycemia and lower incidence of retinopathy and nephropathy (9,11).”
From Persistence of prolonged C-peptide production in type 1 diabetes as measured with an ultrasensitive C-peptide assay (2012) · cites this paper as [11]
In the citing paper
“The strongest evidence to date, however, finds that while higher and sustained levels of C-peptide are most beneficial, even modest levels of β-cell function in some with long-term disease are associated with lower rates of hypoglycemia and lower incidence of retinopathy and nephropathy (9,11).”
From Persistence of prolonged C-peptide production in type 1 diabetes as measured with an ultrasensitive C-peptide assay (2012) · cites this paper as [11]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Statistical Methods in Cancer Research. Volume II – The Design and Analysis of Cohort Studies
Juul, S. (1989) · Scandinavian Journal of Social Medicine · doi:10.1177/140349488901700214 · Cited by 3,602
The design and analysis of cohort studies
Breslow, N. E., & Day, N. E. (1987) · International Agency for Research on Cancer eBooks · Cited by 1,312
The Diabetes Control and Complications (DCCT) Research Group (1995) · Kidney International · doi:10.1038/ki.1995.236 · Cited by 694
Gerich, J. E., Langlois, M., Noacco, C., Karam, J. H., & Forsham, P. H. (1973) · Science · doi:10.1126/science.182.4108.171 · Cited by 688
(1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-128-7-199804010-00001 · Cited by 546
The DCCT Research Group (1986) · Diabetes · doi:10.2337/diabetes.35.5.530 · Cited by 466
(1995) · Archives of Ophthalmology · doi:10.1001/archopht.1995.01100010038019 · Cited by 325
Hypoglycemia: The Limiting Factor in the Management of IDDM
Cryer, P. E. (1994) · Diabetes · doi:10.2337/diab.43.11.1378 · Cited by 307
THE DCCT RESEARCH GROUP (1987) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-65-1-30 · Cited by 215
Flagged first, then by citations
Cited by
Sorted by citations
Items 301–400 of 697
Immunotherapy for type 1 diabetes
Allen, L. A., & Dayan, C. M. (2021) · British Medical Bulletin · doi:10.1093/bmb/ldab027 · Cited by 24
Synergistic effects of C-peptide and insulin on low O2-induced ATP release from human erythrocytes
Richards, J. P., Stephenson, A. H., Ellsworth, M. L., & Sprague, R. S. (2013) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00341.2013 · Cited by 23
LeFevre, J., Cyriac, S. L., Tokmic, A., & Pitlick, J. M. (2022) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxac244 · Cited by 22
Baidal, D. A., Ballou, C., Rickels, M. R., Berney, T., Pattou, F. N., Payne, E. H., Barton, F. B., Alejandro, R., & CITR Investigators (2023) · Diabetes Care · doi:10.2337/dc22-1155 · Cited by 24
Pant, T., Lin, C., Bedrat, A., Jia, S., Roethle, M. F., Truchan, N. A., Ciecko, A. E., Chen, Y., & Hessner, M. J. (2024) · Science Advances · doi:10.1126/sciadv.adn2136 · Cited by 22
Sørensen, J., Vaziri‐Sani, F., Maziarz, M., Kristensen, K., Ellerman, A., Breslow, N. E., Lernmark, Å., Pociot, F., Brorsson, C., & Birkebæk, N. (2012) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2011.12.013 · Cited by 22
Efficacy and safety of otelixizumab use in new-onset type 1 diabetes mellitus
Guglielmi, C., Williams, S. R., Toro, R. D., & Pozzilli, P. (2016) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2016.1180363 · Cited by 22
Li, J., & Lian, H. (2016) · Archives of Pharmacal Research · doi:10.1007/s12272-016-0762-4 · Cited by 23
Residual β-Cell Function and Male/Female Ratio Are Higher in Incident Young Adults Than in Children
Bruno, G., Cerutti, F., Merletti, F., Cavallo‐Perin, P., Gandolfo, E., Rivetti, M., Runzo, C., Pinach, S., Pagano, G., & The Piedmont Study Group for Diabetes Epidemiology (2005) · Diabetes Care · doi:10.2337/diacare.28.2.312 · Cited by 22
Latent (slowly progressing) autoimmune diabetes in adults
Seißler, J. (2008) · Current Diabetes Reports · doi:10.1007/s11892-008-0018-x · Cited by 22
Preserved Proinsulin Secretion in Long-Standing Type 1 Diabetes
Steenkamp, D., Cacicedo, J. M., Sahin-Efe, A., Sullivan, C. A. W., & Sternthal, E. (2017) · Endocrine Practice · doi:10.4158/ep-2017-0009 · Cited by 22
Williams, M. D., Bacher, R. L., Perry, D. J., Grace, C. R., MCGRAIL, K. M., Posgai, A. L., MUIR, A. B., Chamala, S., Haller, M. J., Schatz, D., et al. (2021) · Diabetes · doi:10.2337/db20-0937 · Cited by 21
Wilhelm-Benartzi, C. S., Miller, S. E., Bruggraber, S. F. A., Picton, D., Wilson, M., Gatley, K., Chhabra, A., Marcovecchio, M. L., Hendriks, E., Morobé, H., et al. (2021) · BMJ Open · doi:10.1136/bmjopen-2021-053669 · Cited by 21
Racial and ethnic differences among children with new‐onset autoimmune Type 1 diabetes
Gandhi, K. K., Tosur, M., Schaub, R., Haymond, M. W., & REDONDO, M. J. (2017) · Diabetic Medicine · doi:10.1111/dme.13408 · Cited by 21
Oh, E., Ahn, M., Afelik, S., Becker, T. C., Roep, B. O., & Thurmond, D. C. (2018) · Diabetes · doi:10.2337/db18-0259 · Cited by 21
Yuan, J., Zhang, L., Jia, P., Zhong, X., & Yang, J. (2021) · International Journal of Endocrinology · doi:10.1155/2021/5539654 · Cited by 21
Giebink, A., Vogel, P. A., Medawala, W., & Spence, D. M. (2012) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2359 · Cited by 21
Proinsulin C-peptide: Friend or foe in the development of diabetes-associated complications?
Nordquist, L. (2008) · Vascular Health and Risk Management · doi:10.2147/vhrm.s3955 · Cited by 21
Bizzarri, C., Benevento, D., Ciampalini, P., Patrizia, P. I., Schiaffini, R., Antonella, M., Ravà, L., & Cappa, M. (2010) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem.2010.180 · Cited by 21
Doc2b Protects β-Cells Against Inflammatory Damage and Enhances Function
Aslamy, A., Oh, E., Olson, E. M., Zhang, J., Ahn, M., Moin, A. S. M., Tunduguru, R., Salunkhe, V. A., Veluthakal, R., & Thurmond, D. C. (2018) · Diabetes · doi:10.2337/db17-1352 · Cited by 21
Truman, L. A., Pękalski, M. Ł., Kareclas, P., Evangelou, M., Walker, N. M., Howlett, J., Mander, A., Kennet, J., Wicker, L. S., Bond, S. J., et al. (2015) · BMJ Open · doi:10.1136/bmjopen-2015-009799 · Cited by 20
Ludvigsson, J., Routray, I., Vigård, T., Hanås, R., Rathsman, B., Carlsson, A., Särnblad, S., Albin, A., Arvidsson, C., Samuelsson, U., et al. (2021) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3440 · Cited by 21
Pinto, C., Ibáñez, M. R., Loyola, G., León, L., Salvatore, Y., González, C., Barraza, V., Castañeda, F., Aldunate, R., Porcia, L. C., et al. (2021) · Nutrients · doi:10.3390/nu13061828 · Cited by 20
Buckingham, B. A., Beck, R. W., Ruedy, K. J., Cheng, P., Kollman, C., WEINZIMER, S. A., DiMeglio, L. A., Bremer, A. A., Slover, R. H., & Cantwell, M. (2013) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2013.0002 · Cited by 20
Willemsen, R. H., Burling, K., Barker, P., Ackland, F., Dias, R. P., Edge, J., Smith, A., Todd, J. A., Lopez, B., Mander, A., et al. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-00500 · Cited by 21
Patient Perception and Satisfaction With Insulin Pump System: Pilot User Experience Survey
Grando, A., Bayuk, M., Karway, G. K., Corrette, K., Groat, D., Cook, C. B., & Thompson, B. (2019) · Journal of Diabetes Science and Technology · doi:10.1177/1932296819843146 · Cited by 20
Nielens, N., Pollé, O. G., Robert, A. R., & Lysy, P. A. (2018) · Journal of Diabetes Research · doi:10.1155/2018/5936360 · Cited by 20
Challenges in developing endpoints for type 1 diabetes intervention studies
Cernea, S., Raz, I., Herold, K. C., Hirshberg, B., Roep, B. O., Schatz, D., Fleming, G. A., Pozzilli, P., Little, R. R., Schloot, N. C., et al. (2009) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.1002 · Cited by 20
Rehabilitation of adaptive immunity and regeneration of beta cells
Pasquali, L., Fan, Y., Trucco, M., & Ringquist, S. (2006) · Trends in biotechnology · doi:10.1016/j.tibtech.2006.08.007 · Cited by 21
A little help from residual β cells has long-lasting clinical benefits
Lam, A. P., Dayan, C. M., & Herold, K. C. (2021) · Journal of Clinical Investigation · doi:10.1172/jci143683 · Cited by 19
Koška, J., Nuyujukian, D. S., Bahn, G., Zhou, J. J., & Reaven, P. D. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01418-z · Cited by 19
Islet transplantation into brown adipose tissue can delay immune rejection
Kepple, J. D., Barra, J. M., Young, M. E., Hunter, C. S., & Tse, H. M. (2022) · JCI Insight · doi:10.1172/jci.insight.152800 · Cited by 19
Shen, S., Li, L., Ouyang, J., Xu, J., & Zhu, D. (2012) · Journal of Diabetes · doi:10.1111/j.1753-0407.2012.00214.x · Cited by 19
Urinary C‐peptide creatinine ratio detects absolute insulin deficiency in Type 2 diabetes
Hope, S. V., Jones, A. G., Goodchild, E., Shepherd, M. H., Besser, R. E. J., Shields, B. M., McDonald, T. J., Knight, B., & Hattersley, A. T. (2013) · Diabetic Medicine · doi:10.1111/dme.12222 · Cited by 19
Insulin Therapy in Type 1 Diabetes
Stephens, E. (2014) · Medical Clinics of North America · doi:10.1016/j.mcna.2014.08.016 · Cited by 21
Brancato, D., Fleres, M., Aiello, V., Saura, G., Scorsone, A., Ferrara, L., Provenzano, F., Noto, A. D., Spanò, L., & Provenzano, V. (2014) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2014.0034 · Cited by 19
Penaforte-Saboia, J. G., Montenegro, R. M., Couri, C. E. B., Batista, L. A. D. A., Montenegro, A. P. D. R., Fernandes, V. O., Akhtar, H., Negrato, C. A., Malmegrim, K. C. R., Moraes, D. A., et al. (2017) · Frontiers in Endocrinology · doi:10.3389/fendo.2017.00331 · Cited by 19
Jamiołkowska‐Sztabkowska, M., Głowińska‐Olszewska, B., Łuczyński, W., Konstantynowicz, J., & Bossowski, A. T. (2020) · Pediatric Diabetes · doi:10.1111/pedi.13018 · Cited by 20
Bolla, A. M., Gandolfi, A., Borgonovo, E., Laurenzi, A., Caretto, A., Molinari, C., Catalano, R. S., Bianconi, E., Monti, P., Sordi, V., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa791 · Cited by 19
Diabetes management: optimizing roles for nurses in insulin initiation
Levich, B. (2011) · Journal of Multidisciplinary Healthcare · doi:10.2147/jmdh.s16451 · Cited by 20
Yu, H. W., Lee, Y. J., Cho, W. I., Lee, Y. A., Shin, C. H., & Yang, S. W. (2015) · Annals of Pediatric Endocrinology & Metabolism · doi:10.6065/apem.2015.20.2.92 · Cited by 19
The clinical potential of low-level C-peptide secretion
Ludvigsson, J. (2016) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2016.1210513 · Cited by 19
Wahren, J. (2003) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.403 · Cited by 19
Hemoglobin A1c Patterns of Youth With Type 1 Diabetes 10 Years Post Diagnosis From 3 Continents
Sherr, J. L., Schwandt, A., Phelan, H., Clements, M. A., Holl, R. W., Benitez‐Aguirre, P., Miller, K. M., Woelfle, J., Dover, T., Maahs, D. M., et al. (2021) · PEDIATRICS · doi:10.1542/peds.2020-048942 · Cited by 18
Kurpiewska, E., Ciężki, S., Jamiołkowska‐Sztabkowska, M., Polkowska, A., Starosz, A., Grubczak, K., Moniuszko, M., Bossowski, A. T., & Głowińska‐Olszewska, B. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1176403 · Cited by 18
Ware, J., Boughton, C. K., Allen, J. M., Wilinska, M. E., Hartnell, S., Thankamony, A., Randell, T. L., Ghatak, A., Besser, R. E. J., Elleri, D., et al. (2024) · Diabetes Care · doi:10.2337/dc24-0360 · Cited by 19
Altering the course of type 1 diabetes: an update on prevention and new-onset clinical trials
Thomas, H. R., & Gitelman, S. E. (2013) · Pediatric Diabetes · doi:10.1111/pedi.12040 · Cited by 18
García-Caballero, M., Martínez-Moreno, J. M., Toval, J. A., Miralles, F., Mínguez, A., Osorio, D., Mata, J. M., & Reyes-Ortiz, A. (2013) · PubMed · doi:10.3305/nh.2013.28.sup2.6712 · Cited by 18
Mesenchymal Stromal Cells to Halt the Progression of Type 1 Diabetes?
Carlsson, P., Korsgren, O., & Blanc, K. L. (2015) · Current Diabetes Reports · doi:10.1007/s11892-015-0616-3 · Cited by 18
Cryer, P. E., & Arbeláez, A. M. (2016) · Wiley eBooks · doi:10.1002/9781118924853.ch35 · Cited by 19
Beese, S. E., Price, M. J., Tomlinson, C. L., Sharma, P., Harris, I. M., Adriano, A., Quinn, L. M., Gada, R., Horgan, T. J., Maggs, F., et al. (2025) · BMC Medicine · doi:10.1186/s12916-025-04201-z · Cited by 18
Current state of antigen-specific immunotherapy for type 1 diabetes
Kreiner, F. F., von Scholten, B. J., Coppieters, K. T., & von Herrath, M. (2021) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000647 · Cited by 17
Antibodies to GAD65 and peripheral nerve function in the DCCT
Hoeldtke, R. D., Hampe, C. S., Bekris, L. M., Hobbs, G., Bryner, K. D., & Lernmark, Å. (2007) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2007.01.009 · Cited by 17
Blasetti, A., Giulio, C. D., Tumini, S., Provenzano, M., Rapino, D., Comegna, L., Prezioso, G., Chiuri, R. M., Franchini, S., Chiarelli, F., et al. (2016) · The Pharmacogenomics Journal · doi:10.1038/tpj.2016.6 · Cited by 17
Complete loss of insulin secretion capacity in type 1A diabetes patients during long‐term follow up
Uno, S., Imagawa, A., Kozawa, J., Fukui, K., Iwahashi, H., & Shimomura, I. (2017) · Journal of Diabetes Investigation · doi:10.1111/jdi.12763 · Cited by 17
Boughton, C. K., Allen, J. M., Tauschmann, M., Hartnell, S., Wilinska, M. E., Musolino, G., Acerini, C. L., Dunger, D. B., Campbell, F., Ghatak, A., et al. (2020) · BMJ Open · doi:10.1136/bmjopen-2019-033500 · Cited by 17
Steck, A. K., Liu, X., Krischer, J. P., Haller, M. J., Veijola, R., Lundgren, M., Ahmed, S. T., Akolkar, B., Toppari, J., Hagopian, W., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa715 · Cited by 17
Pinheiro, M. M., Pinheiro, F. M. M., de Arruda, M. M., Beato, G. M., Verde, G. A. C. L., Bianchini, G., Casalenuovo, P. R. M., Argolo, A. A. A., de Souza, L. T., Pessoa, F. G., et al. (2023) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-3997000000652 · Cited by 17
Trials in the Prevention of Type 1 Diabetes: Current and Future
Wherrett, D. K. (2014) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2014.05.004 · Cited by 17
Factors associated with preservation of C-peptide levels at the diagnosis of type 1 diabetes
Szypowska, A., Groele, L., Wysocka‐Mincewicz, M., Mazur, A., Lisowicz, L., Beń‐Skowronek, I., Sieniawska, J., Klonowska, B., Charemska, D., Nawrotek, J., et al. (2018) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2018.03.009 · Cited by 17
Nasr, M. B., D’Addio, F., Malvandi, A. M., Faravelli, S., Castillo‐Leon, E., Usuelli, V., Rocchio, F., Letizia, T., Essawy, A. B. E., Assi, E., et al. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01387 · Cited by 17
Type 1 diabetes mellitus: primary, secondary, and tertiary prevention
Bollyky, J., Sanda, S., & Greenbaum, C. J. (2008) · Mount Sinai Journal of Medicine A Journal of Translational and Personalized Medicine · doi:10.1002/msj.20054 · Cited by 17
C‐peptide an adequate endpoint in type 1 diabetes
Ludvigsson, J. (2009) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.1035 · Cited by 17
Infante, M., Silvestri, F., Padilla, N., Pacifici, F., Pastore, D., Pinheiro, M. M., Caprio, M., Tesauro, M., Fabbri, A., Novelli, G., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14041303 · Cited by 18
Fasting and meal‐stimulated serum C‐peptide in long‐standing type 1 diabetes mellitus
Vollenbrock, C. E., Mul, D., Dekker, P., Birnie, E., de Vries, M., Boesten, L. S. M., Groen, J., Geelhoed-Duijvestijn, P. H. L. M., Aanstoot, H., & Wolffenbuttel, B. H. R. (2022) · Diabetic Medicine · doi:10.1111/dme.15012 · Cited by 17
Pozzilli, P., Raz, I., Peled, D., Elias, D., Avron, A., Tamir, M., Eren, R., Dagan, S., & Cohen, I. R. (2014) · Diabetes Care · doi:10.2337/dc13-1392 · Cited by 16
RetractedKetoacidosis at diagnosis in childhood-onset diabetes and the risk of retinopathy 20years later
Salardi, S., Porta, M., Maltoni, G., Cerutti, F., Rovere, S., Iafusco, D., Tumini, S., Cauvin, V., Zucchini, S., Cadario, F., et al. (2015) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2015.10.009 · Cited by 16
Factor analysis of diabetic retinopathy in Chinese patients
Zheng, W. (2011) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2011.02.007 · Cited by 16
Li, X., Cheng, J., & Zhou, Z. (2016) · Journal of Diabetes · doi:10.1111/1753-0407.12376 · Cited by 16
Russo, C., Lazzaro, V., Gazzaruso, C., Maurotti, S., Ferro, Y., Pingitore, P., Fumo, F., Coppola, A., Gallotti, P., Zambianchi, V., et al. (2016) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2016.12.012 · Cited by 16
DiaPep277® and immune intervention for treatment of type 1 diabetes
Schloot, N. C., & Cohen, I. R. (2013) · Clinical Immunology · doi:10.1016/j.clim.2013.09.001 · Cited by 16
DiaPep277 peptide therapy in the context of other immune intervention trials in type 1 diabetes
Tuccinardi, D., Fioriti, E., Manfrini, S., D'Amico, E., & Pozzilli, P. (2011) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2011.599319 · Cited by 15
Wong, T. W. C., Wong, M. Y. S., & But, W. (2021) · Annals of Pediatric Endocrinology & Metabolism · doi:10.6065/apem.2040202.101 · Cited by 15
Chen, M., Wang, Y., Feng, P., Liang, Y., Liu, Q., Yang, M., Lu, C., Shi, P., Cheng, J., Ji, A., et al. (2023) · Journal of Diabetes Research · doi:10.1155/2023/5919468 · Cited by 15
Marchi, U. D., Hermant, A., Thévenet, J., Ratinaud, Y., Domingo, J. S., Barron, D., & Wiederkehr, A. (2017) · Journal of Cell Science · doi:10.1242/jcs.200741 · Cited by 16
Type 1 Diabetes: Disease Stratification
Insel, R. A., Dutta, S., & Hedrick, J. A. (2017) · Biomedicine Hub · doi:10.1159/000481131 · Cited by 17
Defining outcomes for beta cell replacement therapy: a work in progress
Piemonti, L., de Koning, E. J. P., Berney, T., Odorico, J. S., Markmann, J. F., Stock, P. G., & Rickels, M. R. (2018) · Diabetologia · doi:10.1007/s00125-018-4588-0 · Cited by 15
Thunander, M., Lindgren, A., Petersson, C., Landin‐Olsson, M., & Holmberg, S. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.107943 · Cited by 15
Bone turnover markers during the remission phase in children and adolescents with type 1 diabetes
Madsen, J. O. B., Herskin, C. W., Zerahn, B., Jensen, A. K., Jørgensen, N. R., Olsen, B. S., Svensson, J., Pociot, F., & Johannesen, J. (2019) · Pediatric Diabetes · doi:10.1111/pedi.12963 · Cited by 15
Insulin is necessary but not sufficient: changing the therapeutic paradigm in type 1 diabetes
Lord, S. M., & Greenbaum, C. J. (2020) · F1000Research · doi:10.12688/f1000research.21801.1 · Cited by 15
Barra, J. M., Kozlovskaya, V., Kepple, J. D., Seeberger, K. L., Kuppan, P., Hunter, C. S., Korbutt, G. S., Kharlampieva, E., & Tse, H. M. (2021) · Xenotransplantation · doi:10.1111/xen.12706 · Cited by 15
Benefits and Hurdles of Pancreatic β-Cell Replacement
Bolla, A. M., Montefusco, L. B., Pastore, I., Lunati, M. E., Nasr, M. B., & Fiorina, P. (2022) · Stem Cells Translational Medicine · doi:10.1093/stcltm/szac058 · Cited by 17
Shim, J. Y., Chung, J. O., Jung, D., Kang, P. S., Park, S., Kendi, A. T., Lowe, V. J., & Lee, S. B. (2023) · PLoS ONE · doi:10.1371/journal.pone.0281496 · Cited by 16
Durana, Y. D. D., Lau, J., Knee, D. A., Filippi, C. M., Londei, M., McNamara, P., Nasoff, M. S., DiDonato, M., Glynne, R. J., & Herman, A. E. (2013) · PLoS ONE · doi:10.1371/journal.pone.0078483 · Cited by 15
Disease modifying therapies in type 1 diabetes: Where have we been, and where are we going?
Lord, S. M., & Greenbaum, C. J. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2015.02.002 · Cited by 15
Diabetes mellitus in childhood: an emerging condition in the 21st century
Manna, T. D., Setian, N., Savoldelli, R. D., Guedes, D. R., Kuperman, H., Filho, H. C. M., Steinmetz, L., Cominato, L., Dichtchekenian, V., & Damiani, D. (2016) · Revista da Associação Médica Brasileira · doi:10.1590/1806-9282.62.06.594 · Cited by 17
Diabetes - Damages and Treatments
Rigobelo, E. C. (2011) · InTech eBooks · doi:10.5772/1823 · Cited by 15
Bellin, M. D., Eaton, A. A., Ramanathan, K. V., Beilman, G. J., Downs, E. M., Schwarzenberg, S. J., Trikudanathan, G., Freeman, M. L., Sutherland, D. E. R., & Chinnakotla, S. (2025) · Journal of the American College of Surgeons · doi:10.1097/xcs.0000000000001294 · Cited by 14
Ludvigsson, J., Routray, I., Elluru, S. R., Leanderson, P., Larsson, H. E., Rathsman, B., Hanås, R., Carlsson, A., Ek, T., Samuelsson, U., et al. (2020) · Future Science OA · doi:10.2144/fsoa-2020-0078 · Cited by 14
DiMeglio, L. A., Cheng, P., Beck, R. W., Kollman, C., Ruedy, K. J., Slover, R. H., Aye, T., WEINZIMER, S. A., Bremer, A. A., & Buckingham, B. A. (2015) · Pediatric Diabetes · doi:10.1111/pedi.12271 · Cited by 14
Immunotherapies in Diabetes Mellitus Type 1
Gupta, S. (2012) · Medical Clinics of North America · doi:10.1016/j.mcna.2012.04.008 · Cited by 14
Nwosu, B. U., Rupendu, S., Zitek‐Morrison, E., Patel, D. P., Villalobos-Ortiz, T. R., Jasmin, G., & BARTON, B. A. (2019) · Journal of the Endocrine Society · doi:10.1210/js.2019-00016 · Cited by 14
Maestroni, A., Ruggieri, D., DellʼAntonio, G., Luzi, L., & Zerbini, G. (2005) · European Journal of Endocrinology · doi:10.1530/eje.1.01823 · Cited by 14
Novel therapy for Type 1 diabetes - autologous hematopoietic stem cell transplantation
Li, L., Gu, W., & Zhu, D. (2012) · Journal of Diabetes · doi:10.1111/1753-0407.12002 · Cited by 16
Barra, J. M., Kozlovskaya, V., Burnette, K., Banerjee, R. R., Fraker, C. A., Kharlampieva, E., & Tse, H. M. (2023) · American Journal of Transplantation · doi:10.1016/j.ajt.2023.01.007 · Cited by 13
Novel Autologous Dendritic Cell Therapy AVT001 for Type 1 Diabetes
Gaglia, J. L., Daley, H., Bryant, N. K., Ritz, J., Dong, T., Skyler, J. S., & Jiang, H. (2024) · NEJM Evidence · doi:10.1056/evidoa2300238 · Cited by 13
Type 1 diabetes: immune pathology and novel therapeutic approaches
Ling, E. M., Lemos, J. R. N., Hirani, K., & von Herrath, M. (2024) · Diabetology International · doi:10.1007/s13340-024-00748-z · Cited by 13
General immune dampening is associated with disturbed metabolism at diagnosis of type 1 diabetes
Rydén, A., Ludvigsson, J., Fredrikson, M. G., & Faresjö, M. (2013) · Pediatric Research · doi:10.1038/pr.2013.167 · Cited by 13
The latest pharmacotherapy options for type 1 diabetes
Ludvigsson, J. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.855197 · Cited by 13
Intensive Therapy in Newly Diagnosed Type 2 Diabetes: Results of a 6-Year Randomized Trial
Harrison, L., ADAMS-HUET, B. A., Li, X., Raskin, P., & Lingvay, I. (2014) · Journal of Investigative Medicine · doi:10.2310/jim.0000000000000068 · Cited by 14
Metadata
- Authors
- Steffes, M. W., Sibley, S., Jackson, M., & Thomas, W.
- Affiliations
- University of Minnesota (US)
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2003-03-01
- Volume
- 26
- Issue
- 3
- Pages
- 832-836
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W1988519907
- Cited by
- 695
- References
- 25
- Citations by year
- 2026: 20 · 2025: 26 · 2024: 30 · 2023: 34 · 2022: 39 · 2021: 49 · 2020: 38 · 2019: 29 · 2018: 31 · 2017: 32 · 2016: 30 · 2015: 44 · 2014: 32 · 2013: 53 · 2012: 37
- FWCI
- 8.55
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Center for Research Resources (M01RR000400, M01-RR00400)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Keywords
- type 1 diabetes, residual beta-cell function, C-peptide, diabetic retinopathy, diabetic nephropathy, albuminuria, severe hypoglycemia, intensive insulin therapy, diabetes complications, Diabetes Control and Complications Trial
- MeSH terms
- Adult, Blood Glucose, C-Peptide, Diabetes Mellitus, Type 1, Diabetic Nephropathies, Diabetic Retinopathy, Female, Glycated Hemoglobin, Humans, Hypoglycemia, Islets of Langerhans, Male, Retrospective Studies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
